R&D instability affecting Australian biotech, says report

23 February 2017

Australian biotech companies might not have Brexit or an unpredictable new President to worry about, but they are being caused uncertainty by a troubling tax issue.

Constant reviews and recent changes to the Research and Development (R&D) Tax Incentive are jeopardizing Australian innovation and prompting the country’s biotechnology firms to reconsider their R&D investment, says research body the McKell Institute.

The public policy institute has examined how R&D policy instability affects the Australian biotechnology industry in a report titled Committing to the Innovation Nation: Why the R&D Tax Incentive is so important for Australia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK